Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of a Neuroprotective Drug to Limit the Extent of Damage From an Ischemic Stroke (MINOS)

This study has been completed.
National Institute of Neurological Disorders and Stroke (NINDS)
University of Kentucky
Oregon Health and Science University
Information provided by (Responsible Party):
David Hess, MD, Georgia Health Sciences University Identifier:
First received: February 28, 2008
Last updated: December 9, 2011
Last verified: December 2011
The primary aim of this study is to find out which of 4 different doses of minocycline are safe and well tolerated so that we will know the optimal dose to test in future patients.

Condition Intervention Phase
Stroke, Acute
Drug: Minocycline
Phase 1
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Minocycline to Improve Neurologic Outcome in Stroke (MINOS)

Resource links provided by NLM:

Further study details as provided by Augusta University:

Primary Outcome Measures:
  • Maximally Tolerated Dose of IV Minocycline [ Time Frame: 3 days ]
    Investigators closely monitored each subject for evidence of minocycline intolerance. All adverse events were immediately reported for a decision whether to discontinue the study medication and/or reduce the dose. A computer program was used to determine the maximum tolerated dose. After entering information regarding doses and expected toxicities, results for each subject as they were collected were entered. The computer program informed as to (de)escalation, or maintenance of the same dose in the subsequent cohort of enrolled patients.

Secondary Outcome Measures:
  • Half-life of IV Minocycline [ Time Frame: For each subject blood samples were drawn before dose #1 and one hour after starting dose #1. Additional blood was drawn 1, 6, 12, 24, 48, and 72 hours after starting dose #6, which lasted approximately 6 days. ]
    In eligible patients enrolled at Georgia Health Sciences University, blood samples were drawn for quantification of minocycline serum concentrations. This enabled the study team to determine the half life of the study drug.

  • 90 Day Modified Rankin Scale Score [ Time Frame: 3 months ]
    The modified Rankin Scale (mRS) was performed in person at the 90 day clinic follow-up appointment. The modified Rankin Scale is a commonly used scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke. The scale runs from 0-6. 0 represents no symptoms. 1 represents no significant disability. 2 represents slight disability. 3 represents moderate disability. 4 represents moderately severe disability. 5 represents severe disability. 6 represents death.

Enrollment: 60
Study Start Date: May 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Minocycline

    Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.

    Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.

    Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.

    Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses

    Other Names:
    • Minomycin
    • Minocycline hydrochloride
    • Minocycline hydrochloride injection
    • Minomycin Intravenous (for drip use)
    • Minomycin Intravenous
    • MINO
Detailed Description:
Minocycline is a widely used antibiotic and is approved by the Food and Drug Administration (FDA) for treatment of infections and acne. However, doctors do not know whether minocycline will work in stroke patients. Its use in stroke patients is experimental. There is a lot of information from experimental stroke studies in animals that minocycline lessens the damage from a stroke and the animals recover better. Since minocycline is generally a very safe drug in humans and does not have a lot of side effects, investigators at Georgia Health Sciences University (formerly the Medical College of Georgia) believe that it might be a safe and effective drug to improve the outcome in patients with stroke.

Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • over 18 years of age
  • acute onset focal neurologic deficit consistent with acute ischemic stroke, or computed tomographic scan consistent with acute cerebral ischemia
  • onset of symptoms less than 6 hours
  • measurable neurologic deficit (National Institutes of Health [NIH] Stroke Scale >/= 1)

Exclusion Criteria:

  • allergy to tetracycline antibiotics
  • women of child-bearing potential
  • known hepatic and/or renal insufficiency
  • Thrombocytopenia
  • history of intolerance to minocycline
  • dizziness at the time of stroke or in the past month (by self-report)
  • aphasia likely to interfere with patients ability to report adverse effects
  • previous functional disability
  • stuporous or comatose
  • presence of another serious illness likely to confound the study
  • unlikely to be available for 90 day follow-up
  • severe stroke (National Institutes of Health [NIH] Stroke Scale >22)
  • undergoing an interventional neuro-radiological intervention in first 12 hour
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00630396

United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40506-0057
United States, Oregon
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
David Hess, MD
National Institute of Neurological Disorders and Stroke (NINDS)
University of Kentucky
Oregon Health and Science University
Principal Investigator: David C Hess, MD Augusta University
  More Information

Responsible Party: David Hess, MD, Professor and Chairman, Georgia Health Sciences University Identifier: NCT00630396     History of Changes
Other Study ID Numbers: R01NS055728-01A1 ( US NIH Grant/Contract Award Number )
07-02-202 ( Other Identifier: GHSU Human Assurance Committee number )
Study First Received: February 28, 2008
Results First Received: August 1, 2011
Last Updated: December 9, 2011

Keywords provided by Augusta University:
tissue plasminogen activator (tPA)
matrix metalloproteinase-9 (MMP-9)
Minocycline to Improve Neurologic Outcome in Stroke (MINOS)
cerebrovascular stroke
cerebrovascular accident
cerebral stroke
cerebrovascular accident (CVA)

Additional relevant MeSH terms:
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Anti-Bacterial Agents
Anti-Infective Agents processed this record on May 25, 2017